As International Clinical Trials day (May 20th) is celebrated around the world, Manchester scientists are driving two groundbreaking early-phase trials that buck tradition by bringing together Asian and Western research sites.
The University of Manchester has today announced the appointment of a world-leading academic, who is playing a pivotal role in nanomedicine - a growing field with potential to benefit patients suffering from neurodegenerative disease and cancer.
Certain types of papilloma virus might actually prevent cervical cancer, according to a new study by researchers from The University of Manchester.
Scientists, including experts at The University of Manchester, have found a near doubling of the number of markers associated with breast, ovarian, and prostate cancer.
Teenage and young adult cancer deaths almost halved in last 30 years but success masks lack of access to clinical trials25 March 2013
The number of teenagers and young adults dying from cancer in Britain has fallen from around 580 per year in the mid-70s (1975-77) to around 300 today (2008-2010), according to a new Cancer Research UK report.
The North West’s leading entrepreneurs have gathered to discuss how business can beat cancer.
The Pancreatic Cancer Research Fund has today (Tuesday 12 March) announced it is funding a £150,000 research project at Cancer Research UK’s Paterson Institute based at The University of Manchester.
Taking omega-3 fish oils could help to protect against skin cancer, according to researchers at The University of Manchester26 February 2013
The team has just carried out the first clinical trial to examine the impact of the fish oils on the skin immunity of volunteers.
Research carried out by scientists at Georgia Institute of Technology and The University of Manchester has revealed new insights into how cells stick to each other and to other bodily structures, an essential function in the formation of tissue structures and organs.
Genetic medicine experts from Manchester Biomedical Research Centre at Saint Mary’s Hospital and The University of Manchester have identified a new gene responsible for causing an inherited form of tumour, known as spinal meningioma.
Two academics from The University of Manchester have come up with a new diet which they believe can help lower the risk of breast cancer.
Adding lung cancer drugs to targeted melanoma treatment could increase survival for certain patients, according to research published in Cancer Discovery today (Monday 11 February).
In a significant breakthrough scientists prove for the first time that breast cancer stem cells, the driving force of a tumour, can be targeted in cells from patients; an approach that could increase the chances of survival for women with aggressive breast cancers.
Defective regulation of the cell cycle leading to uncontrolled growth is one of the hallmarks of cancer.
Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.
A new paper published this month demonstrates that when it comes to activating cell division, location is everything.
A scientist from The University of Manchester has been awarded a €150,000 (about £120,000) research prize for the development of scalpel-sparing tests for the diagnosis and management of cancer.
Inspirational cancer survivors will take the first step in helping to build a new £28.5m research building for the Manchester Cancer Research Centre (MCRC) today (Thursday).
Cancer research in Manchester has been given a £12.8 million funding boost following a successful bid by The University of Manchester to the UK Research Partnership Investment Fund (UKRPIF).
Scientists have identified a molecular ‘flag’ in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.
Scientists have discovered a molecular ‘tell’ in laboratory experiments that could help doctors determine the severity of a patient’s prostate cancer.
Manchester City Council’s Chief Executive Sir Howard Bernstein will be the next Chair of the Manchester Academic Health Science Centre (MAHSC).
UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body’s own immune system, after highly promising early laboratory results.
Scientists have developed a more accurate technique for imaging brain tumours that explains why different parts of the tumour have a different response to some anticancer drugs.
A study of mechanisms that regulate cell division will better our understanding of the basic molecular processes that may lead to cancer.
Manchester scientists have found a new way of getting valuable information from tissue samples – even from those that have been stored for a long time and have started to reach the end of their shelf-life.
Joana Senra, a final year PhD student in Ian Stratford’s group in the School of Pharmacy & Pharmaceutical Sciences has been awarded the Jack Fowler award for her work on targeting DNA damage response pathways to improve the outcome of radiotherapy.
Manchester scientists have identified a new risk factor associated with a high risk of relapse for childhood leukaemia.
Scientists have found a novel DNA repair protein providing fresh insight into the processes of DNA damage that can lead to cancer.
Scientists have discovered a new regulatory mechanism of cell cycle progression, giving insights into the mechanisms that may cause cancer.
Manchester scientists have synthesised new compounds that can make tumour cells more sensitive to radiotherapy and that could be used to improve cancer treatment.
One of The Christie's clinical scientists, Carl Rowbottom, has received the Chief Scientific Officer's Award for Leadership in the prestigious Advancing Healthcare Awards.
His Royal Highnesses The Earl of Wessex officially opened The Christie's Oak Road Patient Treatment Centre on Wednesday 11 April 2012.
The Department of Health has confirmed that up to £250m will be invested in building Proton Beam Therapy facilities at The Christie and University College London Hospitals NHS Foundation Trust.
Plans to build a state-of-the-art cancer research building for the Manchester Cancer Research Centre (MCRC) have been approved by Manchester City Council’s planning committee.
Zelboraf (vemurafenib), the first personalised treatment to extend life of patients with BRAF V600 mutation positive unresectable or metastatic melanoma to over a year, is now licensed for use in the UK following accelerated review by the EU Commission.
The Christie successfully obtained £4.5M funding from the National Institute for Health Research (NIHR) for its Phase I/II Cancer Trials Unit in recognition of the outstanding early phase research work already carried out.
Professor Richard Marais, the new Director of the Paterson Institute for Cancer Research, took up his post on 1 February 2012.
Dr Nick Slevin has been appointed as the Chair of a new national advisory group on radiotherapy.
Dr Andrew Wardley has been appointed director of the Clinical Trials Unit at The Christie.